BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18190823)

  • 1. Gene polymorphisms in bladder cancer.
    Franekova M; Halasova E; Bukovska E; Luptak J; Dobrota D
    Urol Oncol; 2008; 26(1):1-8. PubMed ID: 18190823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology of DNA repair genes in bladder cancer.
    Kiltie AE
    Methods Mol Biol; 2009; 472():281-306. PubMed ID: 19107438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder Cancer Working Group report.
    Kakehi Y; Hirao Y; Kim WJ; Ozono S; Masumori N; Miyanaga N; Nasu Y; Yokomizo A
    Jpn J Clin Oncol; 2010 Sep; 40 Suppl 1():i57-64. PubMed ID: 20870921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphism of N-acetyltransferase and glutathione S-transferase related to neoplasm of genitourinary system. Minireview.
    Reszka E; Wasowicz W
    Neoplasma; 2002; 49(4):209-16. PubMed ID: 12382017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India.
    Srivastava DS; Mandhani A; Mittal RD
    Arch Toxicol; 2008 Sep; 82(9):633-9. PubMed ID: 18200441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1).
    Narter KF; Ergen A; Agaçhan B; Görmüs U; Timirci O; Isbir T
    Anticancer Res; 2009 Apr; 29(4):1389-93. PubMed ID: 19414392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modified host cell reactivation assay to measure DNA repair capacity for removing 4-aminobiphenyl adducts: a pilot study of bladder cancer.
    Lin J; Kadlubar FF; Spitz MR; Zhao H; Wu X
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1832-6. PubMed ID: 16030125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular genetic model of human bladder carcinogenesis.
    Reznikoff CA; Kao C; Messing EM; Newton M; Swaminathan S
    Semin Cancer Biol; 1993 Jun; 4(3):143-52. PubMed ID: 8318690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort.
    Fontana L; Bosviel R; Delort L; Guy L; Chalabi N; Kwiatkowski F; Satih S; Rabiau N; Boiteux JP; Chamoux A; Bignon YJ; Bernard-Gallon DJ
    Anticancer Res; 2008; 28(3B):1853-6. PubMed ID: 18630471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variants of the cytochrome P450 and glutathione S-transferase associated with risk of bladder cancer in a south-eastern Chinese population.
    Shao J; Gu M; Zhang Z; Xu Z; Hu Q; Qian L
    Int J Urol; 2008 Mar; 15(3):216-21. PubMed ID: 18304215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder cancer epidemiology and pathogenesis.
    Ross RK; Jones PA; Yu MC
    Semin Oncol; 1996 Oct; 23(5):536-45. PubMed ID: 8893866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in one-carbon metabolism pathway genes and risk for bladder cancer in a Tunisian population.
    Rouissi K; Ouerhani S; Oliveira E; Marrakchi R; Cherni L; Ben Othman F; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; Amorim A; Prata MJ; Benammar Elgaaied A
    Cancer Genet Cytogenet; 2009 Nov; 195(1):43-53. PubMed ID: 19837268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of RAS family genes in urothelial carcinoma.
    Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
    J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma.
    Wang YH; Yeh SD; Shen KH; Shen CH; Juang GD; Hsu LI; Chiou HY; Chen CJ
    Toxicol Appl Pharmacol; 2009 Nov; 241(1):111-8. PubMed ID: 19686770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer.
    Ye Y; Yang H; Grossman HB; Dinney C; Wu X; Gu J
    Cancer; 2008 Jun; 112(11):2467-74. PubMed ID: 18361427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and genetic susceptibility to bladder cancer.
    Wu X; Ros MM; Gu J; Kiemeney L
    BJU Int; 2008 Nov; 102(9 Pt B):1207-15. PubMed ID: 19035883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epidemiology of bladder and kidney cancer.
    Scélo G; Brennan P
    Nat Clin Pract Urol; 2007 Apr; 4(4):205-17. PubMed ID: 17415353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer.
    Ahirwar D; Mandhani A; Mittal RD
    Arch Med Res; 2009 Feb; 40(2):97-102. PubMed ID: 19237018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleotide excision repair, oxidative damage, DNA sequence polymorphisms, and cancer treatment.
    Hutsell SQ; Sancar A
    Clin Cancer Res; 2005 Feb; 11(4):1355-7. PubMed ID: 15746031
    [No Abstract]   [Full Text] [Related]  

  • 20. [Study on polymorphisms in metabolic enzyme genes, DNA repair genes and individual susceptibility to childhood leukemia].
    Zhu R; Xia Z
    Wei Sheng Yan Jiu; 2004 Sep; 33(5):635-8. PubMed ID: 15612500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.